It’s common for people with advanced systemic mastocytosis to think about how much time they have left to live, according to interviews with patients about what it was like to live with the disease.

Introduction: Rare Disease, Expanding MarketThe Systemic Mastocytosis Treatment Market is evolving rapidly, driven by rising awareness of rare diseases, breakthroughs in biologic therapies, and ...

Indolent Systemic Mastocytosis Poses a Significant Quality of Life Burden —These investigators estimated the Disability-Adjusted Life Years for ISM to assess the high burden of this disease ...

Video: Determining Indolent vs. Progressive Systemic Mastocytosis —What pushes a diagnosis toward the severe end of the spectrum? Dr. Aaron T. Gerds of Cleveland Clinic Lerner College of ...

Retail chatter around Cogent Biosciences surged on Tuesday as multiple firms raised their price targets following strong results from the Phase 3 Summit trial of bezuclastinib in non-advanced ...

Altered B-cell, plasma cell and antibody immune profiles in blood of systemic mastocytosis Journal: The Journal of Allergy and Clinical Immunology Published: 2024-10-17 DOI: 10.1016/j.jaci.2024.10.005 ...

Cogent Biosciences (NASDAQ:COGT) surged ~31% Monday after releasing positive mid-stage data on bezuclastinib, its candidate for non-advanced systemic mastocytosis. Bezuclastinib met its primary ...

The company plans to launch the first version of its AI Advocate tool, aimed at helping patients manage and guide their ...